Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03547973 · ClinicalTrials.gov registry record · Phase 2

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

A Phase 2 study of Metastatic Urothelial Cancer, sponsored by Gilead Sciences.

Recruiting
Registry status
Phase 2
Development phase
827
Enrollment target
20
Study locations

NCT03547973 is a Phase 2 study of Metastatic Urothelial Cancer that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 827 participants, above the 487-participant average among 5 other Metastatic Urothelial Cancer trials with a reported enrollment target (70% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03547973, a Phase 2 study of Metastatic Urothelial Cancer, is actively recruiting participants, sponsored by Gilead Sciences.

RECRUITING
Registry status
Phase 2
Development phase
827 participants
Enrollment target
20
Study locations

Study Summary

The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).

Conditions Studied

Metastatic Urothelial Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG Cisplatin
  • DRUG Zimberelimab
  • DRUG Avelumab
  • DRUG Sacituzumab Govitecan-hziy

Study Locations (20)

Florida

  • Mount Sinai Comprehensive Cancer Center - Miami Beach
  • Woodlands Medical Specialists, PA - Pensacola
  • Moffitt Cancer Center - Tampa

Illinois

  • University of Illinois Cancer Center - Chicago
  • University of Chicago Medical Center - Chicago
  • Southern Illinois University School of Medicine, Simmons Cancer Institute - Springfield

California

  • USC/Norris Comprehensive Cancer Center - Los Angeles
  • University of California San Francisco - San Francisco

Connecticut

  • Smilow Cancer Hospital at Yale-New Haven - New Haven
  • Eastern Connecticut Hematology and Oncology Associates - Norwich

Michigan

  • University of Michigan - Ann Arbor
  • Karmanos Cancer Institute - Detroit

Arizona

  • The University of Arizona Cancer Center-North Campus - Tucson

Colorado

  • Rocky Mountain Cancer Centers - Littleton

Georgia

  • Winship Cancer Institute, Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 827 participants
Start Date 2018-08-13
Est. Completion 2030-04
Phase Phase 2

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03547973

The ClinicalTrials.gov registry entry for NCT03547973 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 827 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 487-participant average among 5 other Metastatic Urothelial Cancer trials with a reported enrollment target (70% higher). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Urothelial Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT03547973 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Illinois, California.

Frequently Asked Questions

What is clinical trial NCT03547973 about?

NCT03547973 is a clinical study titled "Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread". The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).

What is the current status of trial NCT03547973?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 827 participants. The study started on 2018-08-13. Estimated completion is 2030-04.

What conditions does trial NCT03547973 study?

This clinical trial studies the following conditions: Metastatic Urothelial Cancer.

What interventions are being tested in trial NCT03547973?

The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), Zimberelimab (DRUG), Avelumab (DRUG), Sacituzumab Govitecan-hziy (DRUG).

Who is sponsoring clinical trial NCT03547973?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03547973 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Urothelial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Urothelial Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.